Money Concepts Capital Corp Purchases 848 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Money Concepts Capital Corp lifted its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 4.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 21,031 shares of the company’s stock after purchasing an additional 848 shares during the quarter. Money Concepts Capital Corp’s holdings in Structure Therapeutics were worth $570,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. Geode Capital Management LLC boosted its position in shares of Structure Therapeutics by 0.7% during the third quarter. Geode Capital Management LLC now owns 45,225 shares of the company’s stock valued at $1,985,000 after purchasing an additional 312 shares in the last quarter. Assetmark Inc. boosted its position in shares of Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after purchasing an additional 719 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after purchasing an additional 1,122 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Structure Therapeutics by 10.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 12,634 shares of the company’s stock valued at $343,000 after purchasing an additional 1,174 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock valued at $158,000 after purchasing an additional 1,420 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Price Performance

GPCR stock opened at $30.02 on Friday. Structure Therapeutics Inc. has a 1-year low of $23.50 and a 1-year high of $62.74. The business has a fifty day moving average price of $29.40 and a 200-day moving average price of $35.03. The stock has a market capitalization of $1.72 billion, a P/E ratio of -40.57 and a beta of -2.76.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. JMP Securities reiterated a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday, December 18th. HC Wainwright reiterated a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday, December 19th. Finally, Stifel Nicolaus assumed coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective for the company. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.